KEYTRUDA® Shows Sustained Survival Benefits in Lung Cancer Treatment
In a recent announcement from Merck & Co., Inc. (NYSE: MRK), data presented at the European Society for Medical Oncology (ESMO) Congress 2025 revealed significant long-term survival benefits associated with the use of KEYTRUDA® (pembrolizumab) in the treatment of non-small cell lung cancer (NSCLC). The findings, derived from several pivotal studies, underscore KEYTRUDA’s effectiveness as both a neoadjuvant and monotherapy treatment option for patients with earlier or advanced stages of NSCLC.
Long-Term Data from KEYNOTE Trials
The results stem from a comprehensive analysis involving multiple studies, including the five-year exploratory follow-up of KEYNOTE-671, which assessed the efficacy of KEYTRUDA in combination with chemotherapy prior to surgery, followed by its use as a single agent post-surgery. This regimen demonstrated a notable improvement in overall survival (OS) and event-free survival (EFS) in patients with resectable stage II, IIIA, or IIIB NSCLC compared to those receiving a placebo. Specifically, the hazard ratio for OS was reported at 0.74, indicating a 26% reduction in the risk of death for those treated with KEYTRUDA.
Furthermore, long-term findings from the KEYNOTE-001, KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 trials highlighted the sustained survival benefits of KEYTRUDA monotherapy, particularly for patients with locally advanced or metastatic NSCLC. For instance, in the KEYNOTE-024 trial, patients with tumors expressing high levels of PD-L1 experienced a median OS of 26.3 months with KEYTRUDA, compared to 13.4 months for those receiving chemotherapy.
Clinical Impact and Future Directions
According to Dr. Marjorie Green, senior vice president and head of oncology at Merck, these long-term results represent a significant milestone in the fight against NSCLC. She emphasized the importance of these findings for patients and their families, highlighting that these results reinforce the role of KEYTRUDA as a standard of care across different stages of the disease.
Dr. Heather Wakelee, principal investigator for KEYNOTE-671, also noted that the positive outcomes observed in overall and event-free survival support the continued use of this pembrolizumab-based regimen in clinical practice. The data presented not only reflect the effectiveness of KEYTRUDA but also point towards the potential for ongoing advancements in lung cancer treatment.
Conclusion
With lung cancer remaining a leading cause of cancer mortality worldwide, the introduction and sustained efficacy of KEYTRUDA in various treatment settings represent a crucial advancement. Merck continues to explore the potential of KEYTRUDA across a wide array of cancers, furthering its commitment to improving patient outcomes through innovative treatments. The company is actively involved in ongoing research and clinical trials aimed at enhancing therapeutic options for patients diagnosed with lung cancer and other malignancies. For further information on the research and developments surrounding KEYTRUDA, visit Merck’s official website.
Related
